Search Results

You are looking at 191 - 200 of 496 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Melinda L. Telli and Ronald M. Witteles

years of adjuvant trastuzumab monotherapy initiated after the completion of (neo)adjuvant chemotherapy and adjuvant radiotherapy versus observation. BCIRG 006 (n = 3222) contained 3 arms, including AC followed by docetaxel, with or without 1 year of

Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study . Gynecol Oncol 2008 ; 108 : 226 – 233 . 55 Hogberg T . Adjuvant chemotherapy

Full access

James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, and M. Catherine Lee

and were more likely to be treated with adjuvant chemotherapy (both P <.0001) ( supplemental eTable 1 , available with this article at JNCCN.org ). After CLND, 44 patients (22%) had an increase in nodal staging ( Table 3 ). Before CLND, 13 patients

Full access

Andrew H. Ko and Christopher H. Crane

this setting. Recent Clinical Trials Examining the Respective Roles of Adjuvant Chemotherapy and Radiation More recently, several large phase III trials conducted in both Europe and the United States have sought to better define the roles and

Full access

Adrienne G. Waks and Ann H. Partridge

pose this question already exist: premenopausal women with hormone receptor–positive breast cancer on the Suppression of Ovarian Function Trial (SOFT) were treated with ovarian suppression starting after administration of adjuvant chemotherapy, where

Full access

Manish A. Shah and David P. Kelsen

to have improved survival in a subset analysis in the First-Line Advanced Gastric Cancer Study (FLAGS), which compared cisplatin/S1 versus cisplatin/fluorouracil (FU). 33 Another example of heterogeneity is shown with adjuvant chemotherapy. In one

Full access

Namrata Vijayvergia, Prashant C. Shah, and Crystal S. Denlinger

prognostic factors (Karnofsky performance scale, weight loss, disease stage, and histology), dyspnea, pain, and nausea. 9 , 14 , 16 , 17 Preoperative dyspnea, adjuvant chemotherapy, extensive surgical resection, and comorbidities also predict for worse QOL

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

would be to allow for medical improvement and/or clinical response that would increase the likelihood of optimal cytoreduction at IDS. Patients treated with NACT and IDS should also receive postoperative adjuvant chemotherapy. In recent years, new

Full access

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld, and Darren R. Feldman

significant decrease was seen in the rate of relapse in patients treated with adjuvant chemotherapy (6% vs 49%; P <.001). However, the survival rates were similar in both arms because of excellent salvage with cisplatin-based chemotherapy. All relapses

Full access

J. Sybil Biermann, Douglas R. Adkins, Robert S. Benjamin, Brian Brigman, Warren Chow, Ernest U. Conrad III, Deborah A. Frassica, Frank J. Frassica, Suzanne George, Kenneth R. Hande, Francis J. Hornicek, G. Douglas Letson, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Neeta Somaiah, and Alan W. Yasko

Chemotherapy is not very effective in chondrosarcomas, especially in conventional and dedifferentiated chondrosarcomas. Although Mitchell et al. 47 reported that adjuvant chemotherapy with cisplatin and doxorubicin was associated with improved survival in